Mechanism of Evodia rutaecarpa in treatment of colorectal cancer based on network pharmacology and experimental verification
Objective To investigate the mechanism of Evodia rutaecarpa in treatment of colorectal cancer based on network pharmacology,molecular docking and experimental verification.Methods The active ingredients of E.rutaecarpa were collected by TCMSP and relevant domestic and foreign literature,targets to colorectal cancer were collected through GeneCards,OMIM and TTD databases.The component-disease intersection targets were analyzed through GO and KEGG analysis.AutoDock vina was used to molecular docking between the core components and the core targets.The effects of isorhamnetin on proliferation and apoptosis of SW480 cells by cell counting kit-8(CCK-8)and flow cytometry.Western blotting was employed to determine the expression levels of TP53,AKT1 and VEGFA.Results The 30 active components of E.rutaecarpa corresponding to 174targets,1 484 corresponding targets for colorectal cancer,and 98 targets for the intersection of the two.GO involve biological processes such as cell proliferation,apoptosis and so on.KEGG enrichment pathways involve cancer pathway,PI3K-Akt signaling pathway.Molecular docking results showed that isorhamnetin had a good affinity with TP53,AKT1,VEGFA.Isorhamnetin can inhibit proliferation of SW480 cell and and promote apoptosis compared with the group.Compared with the control group,isorhamnetin down-regulated the expression of AKT1 and VEGFA(P＜0.01)and up-regulated the expression of TP53(P＜0.01).Conclusion E.rutaecarpa can play a role in treatment of colorectal cancer through multi-component,multi-target and multi-pathway pathways,and isorhamnetin is the main active ingredient.
NETL
NSTL
万方数据
维普
